Cerebroprotein hydrolysate, a prescription injection made from pig brain, is used for stroke, dementia and head injury but is not approved in the United States. It modestly speeds early stroke recovery and gives small short-term thinking gains in dementia. For healthy adults the evidence is thin; aging findings come from animals only. Trial harms are mostly mild, though allergic reactions and rare seizures are recognized. Product source matters. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum creatinine with eGFR | 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women | Safety check: severe renal impairment stops use |
| Blood pressure | Below 120/80 mmHg | Safety check: rapid infusion and MAOI combinations shift pressure |
| Cognitive score (MoCA) | No established target; change from own baseline | Marker expected to change: trials measured cognitive scores |
| Serum BDNF | No established target; change from own baseline | Marker expected to change: rose in Alzheimer's patients |
Cadence: Baseline before a first course (BDNF optional); blood pressure at the first infusion, then weekly during each four-week course; cognitive testing at the end of each course and again three months later; creatinine before every subsequent course, typically every three to six months